Drugs / MenACWY-TT
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01782066 | Jan 2013 → Feb 2014 | meningococcal infection | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05082285 | Nov 2021 → Mar 2025 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00356369 | Dec 2006 → Sep 2007 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03189745 | Aug 2017 → Apr 2018 | meningococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03694405 | Sep 2018 → Aug 2021 | meningococcal infection | Canadian Immunization Research Network | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01994629 Comparator | Nov 2013 → Apr 2014 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2/3 | NCT01192997 Comparator | Jun 2012 → Oct 2013 | meningococcal meningitis | Public Health England | Completed | No outcome recorded |
| Phase 3 | NCT05093829 Comparator | Mar 2022 → Mar 2023 | meningococcal meningitis | Emory University | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY-TT | “Different fractional doses of two quadrivalent meningococcal conjugate vaccines (MenACWY-CRM197 (Menveo®) and MenACWY-TT (Nimenrix®)) were administered intradermally to...” PMID 29778515 ↗ May 20187“We evaluated the bactericidal antibody persistence and safety of the quadrivalent meningococcal serogroups A, C, W and Y tetanus-toxoid conjugate vaccine (MenACWY-TT) and the...” PMID 26437712 ↗ Oct 2015 |
| Known as | Nimenrix(Registered) | “A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED...” NCT03189745 ↗ |
| Modality | Vaccine | “tetanus-toxoid conjugate vaccine” PMID 26437712 ↗ Oct 2015 |
| Route | Intramuscular | “One intramuscular dose.” NCT00356369 ↗ |